Rapid detection of SMARCB1 sequence variation using high resolution melting by Dagar, Vinod et al.
          Deakin Research Online 
 
This is the published version:  
 
Dagar, Vinod, Chow, Chung-Wo, Ashley, David M. and Algar, Elizabeth M. 2009, Rapid 
detection of SMARCB1 sequence variation using high resolution melting, BMC cancer, vol. 
9, no. article 437, pp. 1-9. 
 
Available from Deakin Research Online: 
    
 
    http://hdl.handle.net/10536/DRO/DU:30052155  
 
 
 
 
 
 
 
 
Reproduced with the kind permission of the copyright owner.  
 
Copyright: 2009,  BioMed Central. 
BioMed CentralBMC Cancer
ssOpen AcceResearch article
Rapid detection of SMARCB1 sequence variation using high 
resolution melting
Vinod Dagar1,3, Chung-Wo Chow2,3, David M Ashley1,3 and 
Elizabeth M Algar*1,3
Address: 1Molecular Oncology Laboratory, Children's Cancer Centre, Murdoch Children's Research Institute, Royal Children's Hospital, 
Flemington Rd, Parkville, 3052, Australia, 2Anatomical Pathology, Royal Children's Hospital, Flemington Rd, Parkville, 3052, Australia and 
3Department of Paediatrics, University of Melbourne, Parkville, 3052, Australia
Email: Vinod Dagar - vinod.dagar@mcri.edu.au; Chung-Wo Chow - cw.chow@rch.org.au; David M Ashley - david.ashley@rch.org.au; 
Elizabeth M Algar* - elizabeth.algar@rch.org.au
* Corresponding author    
Abstract
Background: Rhabdoid tumors are rare cancers of early childhood arising in the kidney, central
nervous system and other organs. The majority are caused by somatic inactivating mutations or
deletions affecting the tumor suppressor locus SMARCB1 [OMIM 601607]. Germ-line SMARCB1
inactivation has been reported in association with rhabdoid tumor, epitheloid sarcoma and familial
schwannomatosis, underscoring the importance of accurate mutation screening to ascertain
recurrence and transmission risks. We describe a rapid and sensitive diagnostic screening method,
using high resolution melting (HRM), for detecting sequence variations in SMARCB1.
Methods: Amplicons, encompassing the nine coding exons of SMARCB1, flanking splice site
sequences and the 5' and 3' UTR, were screened by both HRM and direct DNA sequencing to
establish the reliability of HRM as a primary mutation screening tool. Reaction conditions were
optimized with commercially available HRM mixes.
Results: The false negative rate for detecting sequence variants by HRM in our sample series was
zero. Nine amplicons out of a total of 140 (6.4%) showed variant melt profiles that were
subsequently shown to be false positive. Overall nine distinct pathogenic SMARCB1 mutations
were identified in a total of 19 possible rhabdoid tumors. Two tumors had two distinct mutations
and two harbored SMARCB1 deletion. Other mutations were nonsense or frame-shifts. The
detection sensitivity of the HRM screening method was influenced by both sequence context and
specific nucleotide change and varied from 1: 4 to 1:1000 (variant to wild-type DNA). A novel
method involving digital HRM, followed by re-sequencing, was used to confirm mutations in tumor
specimens containing associated normal tissue.
Conclusions: This is the first report describing SMARCB1 mutation screening using HRM. HRM
is a rapid, sensitive and inexpensive screening technology that is likely to be widely adopted in
diagnostic laboratories to facilitate whole gene mutation screening.
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Rhabdoid tumors (RT) are a rare tumour of infancy and
early childhood and mainly arise in the kidney and in the
central nervous system where they are referred to as atyp-
ical teratoid rhabdoid tumors (AT/RT). The majority of RT
(85%) are characterized by deletion of chromosome 22q,
and associated inactivating mutations or deletions, affect-
ing tumour suppressor SMARCB1 [OMIM 601607] [1,2].
Few other consistent cytogenetic abnormalities have been
described in RT. Rhabdoid tumors are highly resistant to
conventional chemotherapies and to radiotherapy and
patients frequently succumb rapidly to the disease.
Most histopathology laboratories confirm the diagnosis
of rhabdoid tumor based on loss of immunostaining for
SMARCB1 protein in the tumor cell nuclei and this corre-
lates well with the presence of inactivating SMARCB1
mutations and with homozygous deletion of the gene
[3,4]. However there have been several reports of germ-
line mutations in SMARCB1 in association with rhabdoid
tumor and with other tumors including epitheloid sar-
coma and familial schwannomatosis [4-9]. Germ-line
mutations have been described in patients where the
rhabdoid tumor has arisen at multiple sites ("rhabdoid
predisposition syndrome") and in cases of familial rhab-
doid tumor where more than one child in a family is
affected [10]. These reports underscore the importance of
somatic tumor SMARCB1 mutation screening in these
cases so that follow-up germline studies may be per-
formed to ascertain both recurrence risk in affected cases
and the transmission risk within affected families.
In this report we describe the validation of a rapid and
sensitive diagnostic screening method, using high resolu-
tion melting (HRM), for detecting sequence variations in
SMARCB1. HRM relies on the principle that DNA
sequence variation produces altered melting characteris-
tics in DNA amplicons. Melting data is captured as a fluo-
rescent signal from intercalating dyes that are evenly
distributed within double-stranded DNA during PCR
amplification, and then later released from the amplicon
during the melting phase [11]. The PCR and melting steps
occur consecutively in a closed tube. Amplicons with
melting profiles that are shifted relative to reference
amplicons of known sequence are selected and any
sequence variation is confirmed by direct amplicon
sequencing. The SMARCB1 mutation screening method
we describe is rapid, sensitive and inexpensive and will be
useful for both diagnostic molecular pathology and
molecular genetics laboratories.
Methods
Rhabdoid tumors were submitted to the laboratory for
somatic SMARCB1 mutation screening. The validation
study described was granted institutional approval in
accordance with the policies of the Human Ethics
Research Committee of the Royal Children's Hospital,
approval number CA29031. DNA was extracted from
fresh frozen tissue or from formalin fixed paraffin-embed-
ded (FFPE) tissue sections using the DNeasy kit (Qiagen)
according to the manufacturer's instructions.
Primers for amplification of genomic DNA were as
described in [1], with modifications to the exon 1 and
exon 5 primer pairs. Exon 1 was divided into two overlap-
ping fragments, Exon 1-1 and Exon 1-2. Primer sequences,
amplicon sizes and annealing temperatures are shown in
Table 1.
PCR and HRM were performed on a Rotorgene 6000 (Qia-
gen, Hilden Germany). Cycling was for 45 cycles with
denaturation for 15 seconds at 95°C, annealing and
extension for 10 seconds each. The extension temperature
was 72°C and the annealing temperature varied according
to the amplicon. PCR mixes used for method validation
were: 1 × Sensimix (Quantace), 10 picomole of each
primer and 0.8 uL EvaGreen Dye (supplied with Sen-
simix) in a 20 ul total reaction volume. 30 ng of DNA was
added to each reaction. Reactions were set up in duplicate.
For exon 1, HRM was performed with ramping from 82°C
to 97°C rising by 0.2°C at each step, for exons 2, 3, 4, 5,
6, 7 and 8, HRM was performed with ramping from 75°C
to 90°C rising by 0.2°C at each step, and for exon 9 ram-
ping was from 80°C to 95°C rising by 0.2°C at each step.
The confidence percentage threshold of the Rotorgene
6000 software was set at 90% for variant scoring. Variants
were selected for sequencing when the melting profile of
at least one of each duplicate sample deviated by more
than 10% from control reference samples. Either two or
three control reference DNA samples of known wild-type
sequence were routinely run in parallel with test samples
and second derivative melting data (difference plot) was
obtained by analysing samples relative to reference sam-
ples. PCR products showing variant melting profiles were
sequenced using big dye terminators by standard methods
using the same primers used in HRM-PCR. Dye was
removed from amplicons prior to sequencing by column
clean-up using the QIA PCR purification kit (50) (Qiagen)
according to the manufacturers instructions. Sequence
traces were screened for mutations using Mutation Sur-
veyor software (Softgenetics PA 16803).
For digital HRM, 240 pg of tumor genomic DNA was aliq-
uoted to a mastermix containing sufficient reagent for
PCR amplification of 40 individual samples, each of 20 ul
reaction volume. Forty individual reactions, containing
on average 6 pg of genomic DNA equivalent to the
amount of DNA in a single diploid cell, were analysed by
HRM. 60 pg of DNA, from each of two individual control
reference DNA samples, was aliquoted to a mastermix suf-Page 2 of 9
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reactions tubes each comprising 6 pg of reference DNA.
Both the 20 reference sample and 40 tumor sample reac-
tions were run simultaneously on the Rotorgene 6000
using the conditons described above appropriate for the
exon analysed. The number of PCR cycles was increased
from 45 to 50 to account for the lesser amount of DNA in
each reaction. Amplicons successfully amplified were sub-
jected to HRM using the conditions described above. The
confidence percentage threshold of the Rotorgene 6000
software was set at 90% for variant scoring. Dye removal
and sequencing were as described above.
Results
The SMARCB1 gene encodes nine exons. Primer
sequences designed to flanking intronic sequences were
used to amplify tumor DNA in the presence of fluorescent
dye and the amplicon was then subjected to HRM within
the same tube. PCR and high resolution melting condi-
tions were initially explored and optimized with several
commercially available fluorescent dyes and HRM reagent
mixes, including Syto 9 (Invitrogen), LC Green plus
(Idaho Technologies) and EvaGreen dye supplied with
the HRM Sensimix (Quantace). We were unable to
amplify GC-rich exon 1 in the presence of the dyes Syto 9
and LC Green Plus using the Hot Star Taq polymerase PCR
reagent mixes (Qiagen) and obtained inconsistent melt-
ing curves for exon 4, however all other exons gave con-
sistent melting profiles with these dyes. Using LC Green
Plus the reaction annealing temperatures were increased
by 2°C relative to those used with the other dyes and PCR
optimization required the addition of MgCl2 for exons 2,
3, 4, 5, 6, 7 and 9 to a final concentration of 2 mM and for
analysis of exon 8, MgCl2 was added to a final concentra-
tion of 2.5 mM. 1 × Q-Solution (Qiagen) was added for
amplification of exons 2, 8, and 9, and 0.5× Q solution
was added for amplification of exons 3 and 4. However
using HRM Sensimix with the EvaGreen dye we were able
to readily amplify all SMARCB1 exons without the addi-
tion of denaturing reagents or MgC12 (as described in
methods above) and subsequently used this reagent for all
mutation screening and method validation.
For method validation, all SMARCB1 exons in fourteen
samples (140 amplicons in total) were screened by both
HRM and direct sequencing. These fourteen samples com-
Table 1: PCR conditions for SMARCB1 mutation screening
Exon Primer Amplicon size
bp
Annealing
temperature
5' Exon 1-1 INI1F actgagggcggcctggtcgt
Snf1Rb ccgaaggtcttgctcagcgc
222 65°C
3' Exon 1-2 Snf1Fb ctctgccgccgcaatgatgatg
INI1R cgacacgcccactaggccac
261 64°C
Exon 2 INI12F ctgcgacccttataatgagc
INI12R gcgagtggttttgaaacagg
213 58°C
Exon 3 INI13F accagcagagtgacccagtg
INI13R agagatgccctggccaggaa
195 60°C
Exon 4 INI14F tcgagcctgacagaggtacagtg
INI14R gaatcagcacggagggtgagt
284 60°C
Exon 5 INI15F ttgcatacctagggctccgg
INI15R cacgtaacacacaggggttg
238 60°C
Exon 6 INI16F tggtgcaatctcttggcatc
INI16R tcagtgctccatgatgacac
277 60°C
Exon 7 INI17F tgggctgcaaaagctctaac
INI17R cgctcacacagagaagtctt
312 60°C
Exon 8 INI18F atccactgggtgccagcagt
INI18R tctgcctggaaagccaggtg
313 60°C
Exon 9 INI19F ccctgtagagccttgggaag
INI19R gcctctgtccttgccagaag
200 60°CPage 3 of 9
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tumors and two blood samples. Melting profiles were
compared to those obtained for three unrelated control
DNA samples representing DNA isolated from peripheral
blood, and were scored as wild-type or variant. Reactions
were set up in duplicate and an amplicon was scored as
variant if the confidence percentage threshold of the
Rotorgene 6000 software yielded a score of <90% for at
least one of duplicate technical replicates, where the melt-
ing curves for each test sample amplicon were normalized
consecutively to each of the selected control samples.
A summary of the results obtained for HRM and direct
amplicon sequencing is shown in Table 2. Two tumors,
3161 and 3180, carried two distinct mutations. In one
tumor, (3161), mutations were identified in both exon 5
and exon 6 and in another tumor, (3180), mutations were
identified in both exon 2 and exon 5. These tumors did
not have allele loss for chromosome 22q suggesting that
each SMARCB1 allele was independently affected by a
mutation. In tumors 3331 and 3641, single mutations
were identified. Two of the twelve tumors in the panel,
had wild-type amplicon melting profiles, and were subse-
quently shown to have homozygous deletion of
SMARCB1 confirmed on southern blotting. Amplicons
analysed from these specimens contained wild-type
sequence and were presumably derived from contaminat-
ing normal tissue. Figure 1 shows representative mutation
screening and sequence data for tumors 3180 and 3161.
Table 2: Validation data for SMARCB1 screening by HRM
Exon Analysed Total Sample 
Number
Coding 
sequence 
mutation 
identified by 
direct 
sequencing
Polymorphism 
identified by 
direct 
sequencing
Wild-type 
melt profiles
Variant melt 
profiles
False Positive 
Melt
False Negative 
melt
Exon 1-1 14 0 0 13 1 1(7.1%) 0
Exon1-2 14 0 14
dinuc GC repeat
0 14 0 0
Exon 2 14 c157C>T (3180)
c157C>T (3641)
0 12 2 0 0
Exon 3 14 0 0 13 1 1(7.1%) 0
Exon 4 14 0 0 13 1 1(7.1%) 0
Exon 5 14 c601C>T (3161)
c569-570 ins18 
(3180)
0 12 2 0 0
Exon 6 14 c795+2delinsAT
GA (3161)
0 12 1 1 (7.1%) 0
Exon 7 14 c933_934insAT 
(3331)
4
(SNPrs35817983)
10 4 0 0
Exon 8 14 0 0 10 4 4 (28.6%) 0
Exon 9 14 0 5
(SNP rs5030613)
9 6 1 (7.1%) 0
Validation was performed on the sample series; 3022, 3073, 3074, 3161, 3180, 3327, 3331, 3356, 3441, 3473, 3474, 3567, 3640 and 3641.Page 4 of 9
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samples was zero, ie samples with normal melt profiles
were found to have no sequence variants on sequencing.
A dinucleotide GC repeat polymorphism in intron 1,
amplified with the Exon 1-2 primer pair, was detected by
HRM as variant in all fourteen samples screened. This
highly variant polymorphism was detected as variant rel-
ative to most selected control samples in which it was also
found to be present in variable repeat copy number. All
mutations previously detected by direct sequencing were
clearly identifiable as shifted melting profiles on HRM. A
polymorphism 3' to exon 7, g38509_38510 indel AA
(NC_000022) (SNP rs35817983) was detected by HRM
in four samples and another polymorphism 5' to exon 9,
g47138G>A (NC_000022) (SNP rs5030613) was
detected in five samples.
False positive sequence variations were detected in six
exons, exon 1-1, exon 3, exon 4, exon 6, exon 8 and exon
9 however the overall false positive rate was low. False
positives were not associated with any detectable
sequence variation. Three false positives were identified in
a single tumor DNA sample (3161) suggesting that DNA
quality may have contributed to the observed variation.
On review, whereas the Abs 260/280 nm was acceptable
for this DNA (1.90), the A260/230 ratio was poor (0.44)
suggesting the presence of small molecule contaminants
in the DNA preparation.
Mutations identified in all rhabdoid tumors screened
including the results of immunohistochemical staining
for SMARCB1 protein, are shown in Table 3. This table
includes tumors screened by direct sequencing only and
tumors screened using both HRM and sequencing. Germ-
line mutation screening was performed on blood from
seven cases. However we did not identify any cases with a
germ-line mutation in SMARCB1.
To determine the sensitivity of HRM for detecting specific
mutations DNA containing pathogenic sequence varia-
tion in SMARCB1 was mixed with control DNA and
screened by HRM. Given that many tumors submitted for
diagnostic screening may be mixtures of malignant and
non-malignant cells it was considered important to estab-
lish the reliability of HRM screening for detecting muta-
tions within these settings. DNA samples with identifiable
SMARCB1 mutations in exons 2, 3, 5, 6 and 9 were mixed
with control DNA to give ratios of mutant to normal DNA
SMARCB1 mutation screening by HRM in tumors 3180 and 3161Figure 1
SMARCB1 mutation screening by HRM in tumors 3180 and 3161. Figure 1 shows HRM difference plots for; (a) exon 
5 in tumor 3180, (b) exon 2 in tumor 3180 and (c) exon 6 in tumor 3161. The melting curves associated with the identified 
sequence variations (shown in red) were clearly distinguishable from the control DNA samples (green lines). HRM data for 
exon 5 in tumor 3161 is shown in Figure 2a. The melting curves shown represent the average melting data of grouped dupli-
cate samples. (d) sequence traces for each mutation detected. The mutation position is indicated by *.Page 5 of 9
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Table 3: Summary of pathogenic mutations identified in rhabdoid tumors
Tumor Exon Mutation relative
to ATG codon
Prediction SMARCB
Protein
Site 22qLOH
1877 Exon 2 c118C>T pARG40STOP Absent Abdominal Yes
1918 None Faint Choroid plexus Yes
1938 Exon 9 c1144delG Frame shift Absent CNS Yes
1993 Exon 3 c325insG Frame shift Absent CNS ND
3022 None Present Renal Yes
3074 Deletion of gene Absent Absent CNS Yes
3161 Exon 5 c601C>T pARG201STOP Absent CNS No
Exon 6 c795+2delinsATGA Splice donor site disrupted
3180 Exon 2 c157C>T pARG53STOP Absent CNS No
Exon 5 c569-570ins18 Frame shift
3349 Deletion of gene Absent Absent Liver No
3331 Exon 7 c933_934insAT Frame shift Absent CNS Yes
3388 Exon 9 c1148delC Frame shift Absent CNS ND
3641 Exon 2 c157C>T pARG53STOP Absent CNS ND
3803 Exon 2 c118C>T pARG40STOP Absent CNS ND
ND; Not determined.
Table 4: Detection sensitivity for SMARCB1 mutations in mosaic mixes of tumor DNA
Exon Tumor Mutation Proportion of tumor DNA: normal DNA
Exon 2 3180 c157C>T 1:4
Exon 5 3180 c569-570ins18 1:4
Exon 3 1993 c325insG 1:4
Exon 5 3161 c601C>T 1:10
Exon 9 3388 c1148delC 1:1000
Exon 6 3161 c795+2delinsATGA 1:1000
BMC Cancer 2009, 9:437 http://www.biomedcentral.com/1471-2407/9/437of 1:2, 1:4, 1:10, 1:20, 1:100 and 1:1000. These ratios are
necessarily approximations because tumor DNA is typi-
cally already a mix with DNA from normal tissue associ-
ated with tumor biopsies. The true ratio of mutant to
normal DNA is difficult to precisely predict and may vary
from sample to sample. Nevertheless when tumor DNA
was mixed with normal DNA in the proportions
described, it was apparent that high detection sensitivities
could be achieved (Table 4). The sensitivity for detection
was both sequence context and variant dependent. The
lowest ratio of mutant to normal DNA for each mutation
at which the threshold remained consistently below the
90% confidence threshold in repeat runs, is shown in
Table 4. HRM data showing the sensitivity for the detec-
tion of specific sequence variants in exon 5 in tumor 3161
(1:10) and in exon 9 in tumor 3388 (1:1000) is shown in
Figures 2a and 2b respectively. We were unable to ascer-
tain the detection limit for all mutations due to insuffi-
cient availability of tumor DNA, however this analysis
demonstrates the sensitivity of HRM for detecting muta-
tions and shows for certain sequence variants a very high
sensitivity can be achieved.
Although HRM has a high sensitivity for detecting
sequence variants, verification of mutations by direct
DNA sequencing in the context of tumor and normal tis-
sue DNA mixtures can sometimes be problematic, neces-
sitating cloning and re-sequencing of the cloned
amplicon, to confirm the presence of a mutation. We
developed a novel strategy combining digital PCR and
HRM (digital HRM) to overcome the requirement for
cloning. In this method tumor DNA was serially diluted in
water such that the final amount of DNA in a single
amplification tube was approximately 6 pg, where 6 pg
represents the amount of DNA a single diploid cell. Forty
individual amplifications from each sample were per-
formed simultaneously alongside ten amplifications from
each of two normal controls. Amplicons were then sub-
jected to HRM and the melting profiles of these amplicons
were analysed to distinguish wild-type from variant
sequences. On average 65% of amplicons were success-
fully amplified at these low concentrations. Amplicons
with wild-type and variant melting curves were sequenced
to ascertain their genotype. In the example shown in Fig-
ure 3, three genotypes were identified in tumor 3641 with
a mutation in exon 2 c157C>T. One genotype depicted by
the red melting curves in Figure 3b contained wild-type
sequence (G at position 157 in the reverse sequence) and
clustered with normal control samples, the second and
most predominant genotype (A at position 157 on reverse
sequence) clustered together (blue melting curves) and a
third less common genotype (G/A) clustered in a third
melting group (orange melting curves). The sequence data
for each genotype is shown in Figure 3a. We interpret this
to show a wild-type genotype derived from normal tissue
DNA, an isolated mutant tumor genotype, and a mixed
genotype present in a sub-population of amplicons. It is
not possible to ascertain the mechanism of tumorigenesis
without performing copy number analysis, however given
the evidence for 22q deletion in rhabdoid tumor in asso-
ciation with SMARCB1 mutation it is likely that c157C>T
is a hemizygous mutation and that the heterozygous gen-
otypes are derived from amplicons where the DNA ampli-
fied is derived from both normal and tumor DNA.
SMARCB1 mutation detection sensitivity using HRMFigure 2
SMARCB1 mutation detection sensitivity using HRM. HRM data showing the sensitivity for the detection of specific 
sequence variants in; (a) exon 5 in tumor 3161, c601C>T (1:10), and (b) exon 9 in tumor 3388, c1148delC (1:1000). The melt-
ing curves shown represent the average melting data of grouped duplicate samples. The grouped normal control data was a 
composite of the duplicate melt data from three distinct biological control DNA samples.Page 7 of 9
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In our experience, once validated for a specific gene, HRM
is a rapid screening method with high sensitivity. How-
ever validation of HRM as a pre-sequencing tool requires
extensive optimisation of both reaction conditions and
reagents to ensure confidence and uniformity in calling
sequence variants. Independent in-house validation by
labs contemplating adopting this technology for diagnos-
tic pre-sequencing mutation screening is strongly recom-
mended. Uniformity in DNA extraction protocols is also
an important factor in the reliability of HRM.
The false negative rate determined in our series was zero.
However the false positive rate was amplicon-dependent
and impacted by trace impurities in the DNA. In the diag-
nostic setting where all variants are sequenced to confirm
their true status, false positives do not present a significant
problem, however the true false negative rate is more dif-
ficult to ascertain unless large tumor series with a diversity
of mutations can be examined. In these circumstances
other diagnostic parameters including negative SMARCB1
protein staining should be used as a guide to assess the
likelihood that pathogenic mutations may have been
missed and to the possibility of homozygous deletion of
the gene, present in up to 20% of rhabdoid tumors. These
deletions will not be detected by either HRM screening
nor by direct sequencing and a false negative could be
reported in such circumstances. Application of alternative
techniques including southern blotting and MLPA is
highly recommended for ascertainment of these cases.
Conclusions
This is the first report describing SMARCB1 mutation
screening using HRM. HRM, once established, yields sig-
nificant savings on analysis time and sequencing costs.
While immuno-histochemical staining for SMARCB1 pro-
tein has greatly facilitated the diagnosis of rhabdoid
tumor, identification of a mutation is necessary for the
ascertainment of the germ-line mutational status. This is
becoming increasingly relevant in line with reports of
associations between SMARCB1 mutation and germ-line
predisposition to both rhabdoid tumor and schwan-
noma, and is an important aspect of clinical management
for these patients [12-14]. While we did not identify any
Isolation of mutations using digital HRMFigure 3
Isolation of mutations using digital HRM. Figure 3 shows sequence traces (3a) for genotypes identified by HRM (3b) fol-
lowing dilution of DNA from tumor 3641 and amplification from 6 pg DNA. Each melting curve is derived from a single ampli-
con. Three genotypes were identified in this tumor as shown in 3b and are depicted by red, blue and orange differential melting 
curves. Green melting curves represent that of wild-type, non-tumor control DNA. The wild-type genotype in sample 3641 
has a G at nucleotide 157 (reverse sequence shown with nucleotide position denoted by *), and the mutant genotype has an A 
at this position. A sub-population with G/A was also identified.Page 8 of 9
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rhabdoid tumor cases with germline SMARCB1 mutation
in our small series, germ-line predisposition has now
been reported in a sufficient number of cases of both
rhabdoid tumor and schwannomatosis to warrant routine
investigation.
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